Aligos Therapeutics (ALGS)

Aligos Therapeutics (ALGS) Financial Statements


Aligos Therapeutics Financial Overview

Aligos Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.948; its P/E ratio is -0.57; Aligos Therapeutics is scheduled to report earnings on August 3, 2023, and the estimated EPS forecast is $-0.49. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue$ 140.00K-$ 4.11M$ 3.69M$ 2.57M
Gross Profit$ 140.00K----
EBIT$ -22.92M$ -21.91M$ -18.95M$ -20.39M$ -35.56M
EBITDA$ -22.29M$ -21.10M$ -18.04M$ -19.50M$ -34.57M
Net Income Common Stockholders$ -22.95M$ -21.94M$ -18.62M$ -19.92M$ -35.62M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 103.91M$ 125.93M$ 142.30M$ 159.34M$ 183.22M
Total Assets$ 121.74M$ 141.86M$ 164.07M$ 182.52M$ 210.47M
Total Debt$ 11.96M$ 12.57M$ 13.03M$ 13.44M$ 14.38M
Net Debt$ -91.95M$ -113.35M$ -129.27M$ -145.91M$ -168.84M
Total Liabilities$ 36.99M$ 146.71M$ 42.06M$ 45.54M$ 57.58M
Stockholders Equity$ 84.75M$ 103.92M$ 122.01M$ 136.98M$ 152.89M
Cash Flow-
Free Cash Flow$ -22.35M$ -16.89M$ -17.14M$ -25.37M$ -20.95M
Operating Cash Flow$ -22.34M$ -16.80M$ -17.14M$ -25.04M$ -20.43M
Investing Cash Flow$ 19.99M$ 11.60M$ 32.48M$ -9.98M$ -60.40M
Financing Cash Flow$ -1.00K$ 101.00K$ -19.00K$ 83.00K$ -21.00K
Currency in USD

Aligos Therapeutics Earnings and Revenue History

Aligos Therapeutics Debt to Assets

Aligos Therapeutics Cash Flow

Aligos Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis